parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in oocytes	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 13767

RASL10A in astrocytes, braak-0.18 (p 0.648) → +0.16 (p 0.680)receipt 13774
RASL10A in dopamine neurons, braak-0.39 (p 0.298) → -0.14 (p 0.725)receipt 13775

receipt 13775: RASL10A in dopamine neurons, braak

power: full sample -0.27 (p 0.281, n 18), 95% CI -0.65 to +0.23. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.29 (p 0.235, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.37 (p 0.127, n 18). could be the mix.
skeptic: leave-one-out range -0.41 to -0.17, sign flips 0; without severely affected donors -0.27 (p 0.281, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RASL10A in dopamine neurons.

case closed: nothing better to follow up.

receipt 13774: RASL10A in astrocytes, braak

power: full sample +0.03 (p 0.901, n 18), 95% CI -0.44 to +0.49. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.03 (p 0.915, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.03 (p 0.922, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.14, sign flips 5; without severely affected donors +0.03 (p 0.901, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RASL10A in astrocytes.

case closed: nothing better to follow up.

loading the receipts